JNCE on NASDAQ
Jounce Therapeutics
American pharmaceutical company based in Cambridge, incorporated in Delaware1
In its 2023 annual report the company says: “We are a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. We have developed a suite of integrated technologies that comprise our Translational Science Platform, enabling us to comprehensively interrogate the cellular and molecular composition of tumors.”57 Its shares trade on NASDAQ under the symbol JNCE.1
Price unavailable
Last updated Oct 21, 2026.
Overview
- TickerJNCE on NASDAQ1
- Industrypharmaceutical industry1
- HeadquartersCambridge1
- Websitejouncetx.com
- Legal formDelaware corporation1
- Incorporated inDE4
- Business address780 Memorial Drive, Cambridge, Ma 021394
- Filer categoryNon-accelerated filer, Smaller reporting company4
- LEI5493004MZJQIV2K8ZT613
- StatusActive3
- LEI statusIssued and current3
- Registered addressC/O CORPORATION SERVICE COMPANY, 89703 Carson City, United States3
- Registered withBusiness Center (Secretary of State), NV202431588743
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $34.9M5 | $67.8M6 | $70.1M7 | $67.1M8 | $78.7M9 | $89.0M10 | $103.3M10 | |
| Operating expenses | $118.0M10 | $134.2M10 | ||||||
| Operating income | -$14.5M5 | -$19.2M6 | -$31.3M7 | $52.8M8 | -$45.1M9 | -$91.1M10 | -$52.2M10 | |
| Income tax | $05 | $36.0K6 | $46.0K7 | $46.0K8 | $14.0K9 | $15.0K10 | $135.0K10 | |
| Net income | -$13.7M5 | -$16.4M6 | -$27.4M7 | $56.8M8 | -$43.8M9 | -$90.9M10 | -$50.9M10 | |
| Earnings per share | -$0.847 | $1.728 | -$1.249 | -$1.8210 | -$0.9910 | |||
| Earnings per share (diluted) | -$0.847 | $1.668 | -$1.249 | -$1.8210 | -$0.9910 | |||
| Shares (weighted, basic) | 49.9M shares10 | 51.7M shares10 | ||||||
| Shares (weighted, diluted) | 49.9M shares10 | 51.7M shares10 |
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Cash | $44.8M6 | $23.6M7 | $47.9M8 | $53.2M9 | $147.5M10 | $95.5M10 | $150.6M10 | |
| Current assets | $151.8M5 | $255.6M6 | $192.2M7 | $173.7M8 | $211.4M9 | $190.8M10 | $197.2M10 | |
| Property, plant and equipment | $4.9M10 | $3.7M10 | ||||||
| Total assets | $271.3M5 | $296.7M6 | $214.5M7 | $205.9M8 | $244.2M9 | $252.7M10 | $212.6M10 | |
| Accounts payable | $1.7M10 | $2.1M10 | ||||||
| Current liabilities | $90.7M5 | $62.6M6 | $65.5M7 | $14.4M8 | $19.3M9 | $18.9M10 | $23.6M10 | |
| Total liabilities | $199.4M5 | $129.6M6 | $110.3M7 | $31.3M8 | $32.9M9 | $28.9M10 | $29.4M10 | |
| Retained earnings | -$241.9M10 | -$292.8M10 | ||||||
| Shareholders’ equity | -$69.1M6 | $167.1M7 | $104.1M8 | $174.6M9 | $211.3M10 | $223.8M10 | $183.1M10 | |
| Shares outstanding | 2.4M shares5 | 32.2M shares6 | 32.9M shares7 | 33.7M shares8 | 41.7M shares9 | 51.3M shares10 | 51.7M shares10 | 52.6M shares10 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | $179.7M5 | -$91.0M6 | -$63.6M7 | -$30.1M8 | -$27.8M9 | -$83.5M10 | -$28.9M10 | |
| Stock-based compensation | $11.5M10 | $10.3M10 | ||||||
| Capital spending | $2.2M5 | $15.1M6 | $1.4M7 | $985.0K8 | $94.0K9 | $373.0K10 | $919.0K10 | |
| Free cash flow | $177.5M | -$106.1M | -$65.0M | -$31.1M | -$27.9M | -$83.9M | -$29.8M | |
| Cash from investing | -$60.5M10 | $83.5M10 | ||||||
| Cash from financing | $92.0M10 | $442.0K10 |
Corporate structure
Jounce Therapeutics is part of a group headed by TANG CAPITAL PARTNERS LP. 4 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Jounce Therapeutics
- Deep Track Capital, LP Filed SC 13G/A on Jounce Therapeutics, latest Feb 14, 2024 (3 filings since Feb 14, 2022)
- Opaleye Management Inc. Filed SC 13G on Jounce Therapeutics, latest Feb 9, 2024 (2 filings since Apr 12, 2023)
- Cowen Financial Products LLC Filed SC 13G/A on Jounce Therapeutics, latest Feb 2, 2024 (3 filings since Apr 22, 2022)
- Bank of America Filed SC 13G on Jounce Therapeutics, latest Feb 14, 2023
- ORBIMED ADVISORS LLC Filed SC 13G/A on Jounce Therapeutics, latest Feb 14, 2023 (2 filings since Feb 11, 2022)
- PFM Health Sciences, LP Filed SC 13G/A on Jounce Therapeutics, latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- RTW INVESTMENTS, LP Filed SC 13G/A on Jounce Therapeutics, latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- Third Rock Ventures II, L.P. Filed SC 13G/A on Jounce Therapeutics, latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- ADAGE CAPITAL PARTNERS GP, L.L.C. Filed SC 13G/A on Jounce Therapeutics, latest Feb 10, 2022
- TANG CAPITAL PARTNERS LP San Diego, California, United States
- Jounce Therapeutics Las Vegas, Nevada, United States
- TLGFY, LLC San Diego, California, United States
- TANG CAPITAL PARTNERS IV, INC. Subsidiary · Las Vegas, Nevada, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Jounce Therapeutics reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $23.1M10 Dec 31, 2022 | $23.0M10 Dec 31, 2021 | +0.7% |
| Accumulated depreciation | $19.4M10 Dec 31, 2022 | $18.1M10 Dec 31, 2021 | +7.4% |
| Property and equipment, net | $3.7M10 Dec 31, 2022 | $4.9M10 Dec 31, 2021 | −23.8% |
| Operating-lease assets (leased space) | $8.6M10 Dec 31, 2022 | $11.9M10 Dec 31, 2021 | −27.6% |
Investments
Leadership
Who has led Jounce Therapeutics, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
- Chief executive officerRichard /ca/ Murray Jan 26, 2017 to Jan 11, 202313
- PresidentKimberlee C. Drapkin May 4, 2023 to May 4, 202314
- PresidentRichard /ca/ Murray Jan 26, 2017 to Jan 11, 202313
- Chief financial officerKimberlee C. Drapkin Jan 26, 2017 to May 4, 202315
- Chief operating officerHugh M. Cole Aug 3, 2022 to Jan 11, 202316
Board members and other officers (14)
- Chief Medical OfficerElizabeth Trehu Jan 26, 2017 to Jan 11, 202317
- Chief Business OfficerHugh M. Cole Dec 21, 2017 to Mar 17, 202218
- Board memberKevin C. Tang May 5, 2023 to May 5, 202319
- Board memberLuisa Salter-Cid Feb 12, 2021 to May 4, 202320
- Board memberJigar Raythatha Sep 15, 2021 to May 4, 202321
- Board memberRobert Iannone Jan 23, 2020 to May 4, 202322
- Board memberBarbara Gayle Duncan Jan 26, 2017 to May 4, 202323
- Board memberCary Pfeffer Jan 26, 2017 to Nov 16, 202124
- Board memberJohn Duncan Higgons Jan 26, 2017 to Jun 28, 202225
- Board memberPerry A. Karsen Jan 26, 2017 to May 4, 202326
- Board memberRichard /ca/ Murray Jan 26, 2017 to May 4, 202313
- Board memberRobert I. Tepper Jan 26, 2017 to Jul 2, 202027
- Board memberRobert Kamen Jan 26, 2017 to May 4, 202328
- Board memberLuis Diaz Oct 23, 2017 to May 4, 202329
Subsidiaries and ownership
Ultimate parent
Ownership links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); each one cites its LEI record.
Timeline
- May 4, 20238-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer30
- Mar 30, 20238-K Executive or director change31
- Mar 27, 20238-K Entered a material agreement; Ended a material agreement; Exit or restructuring costs32
- Mar 15, 20238-K Other events33
- Mar 13, 20238-K Regulation FD disclosure34
- Feb 23, 20238-K Entered a material agreement; Exit or restructuring costs; Unregistered sale of shares35
- Jan 20, 20238-K Executive or director change; Other events36
- Jan 5, 20238-K Listing notice or transfer37
- Dec 27, 20228-K Entered a material agreement; Regulation FD disclosure38
- Dec 20, 20228-K Executive or director change39
- Nov 10, 20228-K Results of operations40
- Aug 30, 20228-K Regulation FD disclosure; Other events41
- Jan 26, 2017New chief executive Richard /ca/ Murray becomes CEO13
- Jan 1, 2013Founded Founded1
Calendar
When it reported results
- Nov 10, 2022Reported quarterly or annual results40
- Aug 4, 2022Reported quarterly or annual results42
- May 5, 2022Reported quarterly or annual results43
- Mar 2, 2022Reported quarterly or annual results44
- Jan 10, 2022Reported quarterly or annual results45
- Nov 4, 2021Reported quarterly or annual results46
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
129 filings to the SEC since October 2021: 3 annual reports, 4 quarterly reports, 20 major events, 39 insider forms, 24 large holders, 39 other. The latest 20:
- Feb 14, 2024SC 13G/A EDGAR
- Feb 9, 2024SC 13G EDGAR
- Feb 2, 2024SC 13G/A COWEN FINANCIAL PRODUCTS LLC EDGAR
- May 15, 202315-12G EDGAR
- May 5, 2023SC 13D/A AMENDMENT NO. 4 EDGAR
- May 5, 20234 FORM 4 SUBMISSION EDGAR
- May 5, 20234 FORM 4 SUBMISSION EDGAR
- May 5, 20233 FORM 3 SUBMISSION EDGAR
- May 4, 2023EFFECT EDGAR
- May 4, 2023EFFECT EDGAR
- May 4, 20234 EDGAR
- May 4, 20234 EDGAR
- May 4, 20234 EDGAR
- May 4, 20234 EDGAR
- May 4, 20234 EDGAR
- May 4, 20234 EDGAR
- May 4, 20234 EDGAR
- May 4, 20234 EDGAR
- May 4, 20234 EDGAR
- May 4, 2023S-8 POS EDGAR
The 129 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
21 open-market trades by officers, directors and large owners since October 2021: 2 buys and 19 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 4, 2023 | MURRAY RICHARD /CA/Director | Sale | 39,228 | $1.85 | $72.6K | Form 4 |
| Mar 14, 2023 | TANG CAPITAL MANAGEMENT LLC10% owner | Buy | 20,286 | $1.02 | $20.7K | Form 4 |
| Mar 13, 2023 | TANG CAPITAL MANAGEMENT LLC10% owner | Buy | 65,701 | $0.99 | $65.0K | Form 4 |
| Jan 10, 2023 | Trehu ElizabethChief Medical Officer | Sale | 5,126 | $1.12 | $5.7K | Form 4 |
| Jan 10, 2023 | MURRAY RICHARD /CA/Director | Sale | 24,879 | $1.12 | $27.9K | Form 4 |
| Jan 10, 2023 | Drapkin Kimberlee CPresident, CFO and Treasurer | Sale | 7,781 | $1.12 | $8.7K | Form 4 |
| Jan 10, 2023 | Cole Hugh MChief Operating Officer | Sale | 9,182 | $1.12 | $10.3K | Form 4 |
| Jan 9, 2023 | Trehu ElizabethChief Medical Officer | Sale | 4,159 | $1.10 | $4.6K | Form 4 |
| Jan 9, 2023 | MURRAY RICHARD /CA/Director | Sale | 20,191 | $1.10 | $22.2K | Form 4 |
| Jan 9, 2023 | Drapkin Kimberlee CPresident, CFO and Treasurer | Sale | 6,315 | $1.10 | $6.9K | Form 4 |
| Jan 9, 2023 | Cole Hugh MChief Operating Officer | Sale | 7,452 | $1.10 | $8.2K | Form 4 |
| Jan 10, 2022 | Trehu ElizabethChief Medical Officer | Sale | 5,378 | $6.65 | $35.8K | Form 4 |
| Jan 10, 2022 | MURRAY RICHARD /CA/Director | Sale | 23,924 | $6.65 | $159.1K | Form 4 |
| Jan 10, 2022 | Drapkin Kimberlee CPresident, CFO and Treasurer | Sale | 8,222 | $6.65 | $54.7K | Form 4 |
| Jan 10, 2022 | Cole Hugh MChief Operating Officer | Sale | 6,205 | $6.65 | $41.3K | Form 4 |
| Jan 7, 2022 | Trehu ElizabethChief Medical Officer | Sale | 3,005 | $7.30 | $21.9K | Form 4 |
| Jan 7, 2022 | MURRAY RICHARD /CA/Director | Sale | 13,370 | $7.30 | $97.6K | Form 4 |
| Jan 7, 2022 | Drapkin Kimberlee CPresident, CFO and Treasurer | Sale | 4,595 | $7.30 | $33.5K | Form 4 |
| Jan 7, 2022 | Cole Hugh MChief Operating Officer | Sale | 3,468 | $7.30 | $25.3K | Form 4 |
| Nov 12, 2021 | TRV GP III, LLC10% owner | Sale | 1,900,000 | $8.38 | $15.9M | Form 4 |
All 21 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Deep Track Capital, LPSC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 202447
- Opaleye Management Inc.SC 13G, 2 filings Apr 12, 2023 to Feb 9, 202448
- Cowen Financial Products LLCSC 13G/A, 3 filings Apr 22, 2022 to Feb 2, 202449
- TANG CAPITAL PARTNERS LPSC 13D/A, 6 filings Mar 6, 2023 to May 5, 202350
- Bank of AmericaSC 13G, 1 filing Feb 14, 202351
- ORBIMED ADVISORS LLCSC 13G/A, 2 filings Feb 11, 2022 to Feb 14, 202352
- PFM Health Sciences, LPSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202353
- RTW INVESTMENTS, LPSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202354
- Third Rock Ventures II, L.P.SC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202355
- ADAGE CAPITAL PARTNERS GP, L.L.C.SC 13G/A, 1 filing Feb 10, 202256
SEC filer profile
How Jounce Therapeutics is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARJounce Therapeutics, Inc.2
- CIK0001640455
- Employer ID (EIN)45-48706342
- Filer statusNon-accelerated filer<br>smaller reporting company2
- Incorporated inDelaware2
- Fiscal year endsDecember 312
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
- Business address780 Memorial Drive, Cambridge, MA 021392
- Phone857-259-38402
- Shares outstanding52,635,468 as of Mar 7, 202310
- Public float$125.4M as of Jun 30, 202210
- On EDGAR sinceApr 29, 20152
- Filings405 in all: 4 (151), 8-K (65), 3 (20), SC 13G/A (19), 10-Q (18), SC 13G (16), UPLOAD (12), 4/A (9)2
All 42 form types
CORRESP (8), DEFA14A (8), 10-K (7), S-8 (7), S-8 POS (7), DEF 14A (5), EFFECT (5), 424B5 (4), SC 13D/A (4), 144 (3), DRS/A (3), DRSLTR (3), SC TO-T/A (3), CT ORDER (2), D (2), POS AM (2), S-3 (2), SC 14D9 (2), SC 14D9/A (2), SEC STAFF LETTER (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERTNAS (1), DRS (1), S-1 (1), S-1/A (1), S-1MEF (1), S-3/A (1), SC 13D (1), SC TO-T (1), SC14D9C (1)
- Latest filingsAnnual report (10-K) Mar 10, 2023
Quarterly report (10-Q) Nov 10, 2022
Proxy statement (DEF 14A) Apr 28, 2022
Latest 8-K (8-K) May 4, 2023
Links
- Websitejouncetx.com1
- Instagramwww.instagram.com/onejounce1
- WikidataQ106760435
- SEC EDGARCIK 1640455
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataJounce Therapeutics on Wikidata
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARKimberlee C. Drapkin, President
- 15
- 16
- 17
- 18SEC EDGARHugh M. Cole, Chief Business Officer
- 19SEC EDGARKevin C. Tang, Board member
- 20SEC EDGARLuisa Salter-Cid, Board member
- 21SEC EDGARJigar Raythatha, Board member
- 22SEC EDGARRobert Iannone, Board member
- 23SEC EDGARBarbara Gayle Duncan, Board member
- 24SEC EDGARCary Pfeffer, Board member
- 25SEC EDGARJohn Duncan Higgons, Board member
- 26SEC EDGARPerry A. Karsen, Board member
- 27SEC EDGARRobert I. Tepper, Board member
- 28SEC EDGARRobert Kamen, Board member
- 29SEC EDGARLuis Diaz, Board member
- 30
- 31SEC EDGARExecutive or director change
- 32
- 33SEC EDGAROther events
- 34SEC EDGARRegulation FD disclosure
- 35
- 36
- 37SEC EDGARListing notice or transfer
- 38
- 39SEC EDGARExecutive or director change
- 40SEC EDGARResults of operations
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57